Cargando…

Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19

Currently an emerging human pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused coronavirus disease 2019 (COVID-19) that has posed a serious threat to public health worldwide. As it is a novel severe pneumonia-type viral disease, no effective therapeutic agen...

Descripción completa

Detalles Bibliográficos
Autores principales: Dinda, Biswanath, Dinda, Manikarna, Dinda, Subhajit, Chakraborty, Mithun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420082/
https://www.ncbi.nlm.nih.gov/pubmed/36060987
http://dx.doi.org/10.1016/j.ejmcr.2022.100079
_version_ 1784777313855995904
author Dinda, Biswanath
Dinda, Manikarna
Dinda, Subhajit
Chakraborty, Mithun
author_facet Dinda, Biswanath
Dinda, Manikarna
Dinda, Subhajit
Chakraborty, Mithun
author_sort Dinda, Biswanath
collection PubMed
description Currently an emerging human pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused coronavirus disease 2019 (COVID-19) that has posed a serious threat to public health worldwide. As it is a novel severe pneumonia-type viral disease, no effective therapeutic agents are available to treat this infection to date, emphasizing an urgent need for development of effective anti-SARS-CoV-2 agents. Based on screening in computational biology and biological in vitro assays, a good number of natural compounds and their synthetic analogues have been confirmed to possess target-specific inhibitory effects against the activity of host and viral proteases, namely, cathepsin-L, TMPRSS2, Sec61, Mpro (3CL-protease), RNA-dependent RNA protease (RdRp), helicase cap-binding proteases eEF1A, eIF4A, eIF4E, which play dominant roles in progression of infection and replication of SARS-CoV-2 virus in host cells. This review paper describes the potent antiviral activity and target-specific anti-proteases activity of some natural compounds and their synthetic analogues against SARS-CoV-2 infection. It will inspire the researchers to unleash their own creativity and to design potent and safe drugs to fight the current COVID-19 pandemic.
format Online
Article
Text
id pubmed-9420082
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-94200822022-08-30 Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19 Dinda, Biswanath Dinda, Manikarna Dinda, Subhajit Chakraborty, Mithun Eur J Med Chem Rep Article Currently an emerging human pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused coronavirus disease 2019 (COVID-19) that has posed a serious threat to public health worldwide. As it is a novel severe pneumonia-type viral disease, no effective therapeutic agents are available to treat this infection to date, emphasizing an urgent need for development of effective anti-SARS-CoV-2 agents. Based on screening in computational biology and biological in vitro assays, a good number of natural compounds and their synthetic analogues have been confirmed to possess target-specific inhibitory effects against the activity of host and viral proteases, namely, cathepsin-L, TMPRSS2, Sec61, Mpro (3CL-protease), RNA-dependent RNA protease (RdRp), helicase cap-binding proteases eEF1A, eIF4A, eIF4E, which play dominant roles in progression of infection and replication of SARS-CoV-2 virus in host cells. This review paper describes the potent antiviral activity and target-specific anti-proteases activity of some natural compounds and their synthetic analogues against SARS-CoV-2 infection. It will inspire the researchers to unleash their own creativity and to design potent and safe drugs to fight the current COVID-19 pandemic. The Author(s). Published by Elsevier Masson SAS. 2022-12 2022-08-28 /pmc/articles/PMC9420082/ /pubmed/36060987 http://dx.doi.org/10.1016/j.ejmcr.2022.100079 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Dinda, Biswanath
Dinda, Manikarna
Dinda, Subhajit
Chakraborty, Mithun
Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19
title Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19
title_full Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19
title_fullStr Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19
title_full_unstemmed Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19
title_short Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19
title_sort some natural compounds and their analogues having potent anti- sars-cov-2 and anti-proteases activities as lead molecules in drug discovery for covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420082/
https://www.ncbi.nlm.nih.gov/pubmed/36060987
http://dx.doi.org/10.1016/j.ejmcr.2022.100079
work_keys_str_mv AT dindabiswanath somenaturalcompoundsandtheiranalogueshavingpotentantisarscov2andantiproteasesactivitiesasleadmoleculesindrugdiscoveryforcovid19
AT dindamanikarna somenaturalcompoundsandtheiranalogueshavingpotentantisarscov2andantiproteasesactivitiesasleadmoleculesindrugdiscoveryforcovid19
AT dindasubhajit somenaturalcompoundsandtheiranalogueshavingpotentantisarscov2andantiproteasesactivitiesasleadmoleculesindrugdiscoveryforcovid19
AT chakrabortymithun somenaturalcompoundsandtheiranalogueshavingpotentantisarscov2andantiproteasesactivitiesasleadmoleculesindrugdiscoveryforcovid19